Zhou Xiao-Dong, Chen Qin-Fen, Targher Giovanni, Byrne Christopher D, Shapiro Michael D, Tian Na, Xiao Tie, Sung Ki-Chul, Lip Gregory Y H, Zheng Ming-Hua
Department of Cardiovascular Medicine, The Heart Center The First Affiliated Hospital of Wenzhou Medical University Wenzhou China.
Medical Care Center The First Affiliated Hospital of Wenzhou Medical University Wenzhou China.
J Am Heart Assoc. 2024 Feb 6;13(3):e032997. doi: 10.1161/JAHA.123.032997. Epub 2024 Jan 19.
Systemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated fatty liver disease. This study aimed to investigate whether serum hs-CRP (high-sensitivity C-reactive protein) levels were associated with the future risk of heart failure (HF) hospitalization in patients with metabolic dysfunction-associated fatty liver disease and a normal left ventricular ejection fraction.
The study enrolled consecutive individuals with metabolic dysfunction-associated fatty liver disease and normal left ventricular ejection fraction who underwent coronary angiography for suspected coronary heart disease. The study population was subdivided into non-HF, pre-HFpEF, and HFpEF groups at baseline. The study outcome was time to the first hospitalization for HF. In 10 019 middle-aged individuals (mean age, 63.3±10.6 years; 38.5% women), the prevalence rates of HFpEF and pre-HFpEF were 34.2% and 34.5%, with a median serum hs-CRP level of 4.5 mg/L (interquartile range, 1.9-10 mg/L) and 5.0 mg/L (interquartile range, 2.1-10.1 mg/L), respectively. Serum hs-CRP levels were significantly higher in the pre-HFpEF and HFpEF groups than in the non-HF group. HF hospitalizations occurred in 1942 (19.4%) patients over a median of 3.2 years, with rates of 3.7% in non-HF, 20.8% in pre-HFpEF, and 32.1% in HFpEF, respectively. Cox regression analyses showed that patients in the highest hs-CRP quartile had a ≈4.5-fold increased risk of being hospitalized for HF compared with those in the lowest hs-CRP quartile (adjusted-hazard ratio, 4.42 [95% CI, 3.72-5.25]).
There was a high prevalence of baseline pre-HFpEF and HFpEF in patients with metabolic dysfunction-associated fatty liver disease and suspected coronary heart disease. There was an increased risk of HF hospitalization in those with elevated hs-CRP levels.
全身慢性炎症在射血分数保留的心力衰竭(HFpEF)和代谢功能障碍相关脂肪性肝病的病理生理学中均起作用。本研究旨在调查血清高敏C反应蛋白(hs-CRP)水平是否与代谢功能障碍相关脂肪性肝病且左心室射血分数正常的患者未来发生心力衰竭(HF)住院的风险相关。
该研究纳入了因疑似冠心病接受冠状动脉造影的连续性代谢功能障碍相关脂肪性肝病且左心室射血分数正常的个体。研究人群在基线时被分为非HF、射血分数保留的心力衰竭前期(pre-HFpEF)和HFpEF组。研究结局为首次因HF住院的时间。在10019名中年个体(平均年龄63.3±10.6岁;38.5%为女性)中,HFpEF和pre-HFpEF的患病率分别为34.2%和34.5%,血清hs-CRP水平中位数分别为4.5mg/L(四分位间距,1.9-10mg/L)和5.0mg/L(四分位间距,2.1-10.1mg/L)。pre-HFpEF组和HFpEF组的血清hs-CRP水平显著高于非HF组。在中位3.2年的时间里,1942名(19.4%)患者发生了HF住院,非HF组、pre-HFpEF组和HFpEF组的发生率分别为3.7%、20.8%和32.1%。Cox回归分析显示,hs-CRP四分位数最高组的患者因HF住院的风险比四分位数最低组增加了约4.5倍(调整后风险比,4.42[95%CI,3.72-5.25])。
在代谢功能障碍相关脂肪性肝病且疑似冠心病的患者中,基线pre-HFpEF和HFpEF的患病率较高。hs-CRP水平升高的患者发生HF住院的风险增加。